Fresenius group in figures
| in million € | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|
| 1 2008 before special items from the APP acquisition; 2009 adjusted for the effects of the mark-to-market accounting of the MEB and the CVR. | |||||
| 2 Net income attributable to Fresenius SE. | |||||
| 3 Equity including noncontrolling interest. | |||||
| 4 Investments in property, plant and equipment and intangible assets, acquisitions. | |||||
| 5 2005: balance sheet adjusted for acquisition of HELIOS Kliniken. | |||||
| 6 2006 pro forma Renal Care Group, excluding earnings from the divestiture of US dialysis clinics as well as their first quarter 2006 earnings. | |||||
| 7 2006 pro forma Renal Care Group, excluding first quarter 2006 earnings of divested US dialysis clinics. | |||||
| 8 Proposal | |||||
| 9 Adjusted for share split in February 2007. | |||||
| 10 2008 pro forma APP Pharmaceuticals and excluding special items from the APP-acquisition. | |||||
| 11 2009 adjusted for the effects of the mark-to-market accounting of the MEB and the CVR. | |||||
| 12 2005 pro forma HELIOS | |||||
| Sales and Earnings | |||||
| Sales | 14,164 | 12,336 | 11,358 | 10,777 | 7,889 |
| EBIT | 2,054 | 1,727 1 | 1,609 | 1,444 | 969 |
| Net income 2 | 514 1 | 450 1 | 410 | 330 | 222 |
| Depreciation and amortization | 562 | 783 | 421 | 399 | 320 |
| Earnings per ordinary share in € | 3.18 1 | 2.85 1 | 2.64 | 2.15 9 | 1.76 9 |
| Earnings per preference share in € | 3.19 1 | 2.86 1 | 2.65 | 2.16 9 | 1.77 9 |
| Cashflow and Balance sheet | |||||
| Operating cash flow | 1,553 | 1,074 | 1,296 | 1,052 | 780 |
| Operating cash flow in % of sales | 11.0 % | 8.7 % | 11.4 % | 9.8 % | 9.9 % |
| Total assets | 20,882 | 20,544 | 15,324 | 15,024 | 11,594 |
| Non-current assets | 15,519 | 15,466 | 11,033 | 10,918 | 8,063 |
| Equity 3 | 7,652 | 6,943 | 6,059 | 5,728 | 5,130 |
| Net debt | 7,879 | 8,417 | 5,338 | 5,611 | 3,250 |
| Net debt / EBITDA 6, 10 | 3.0 | 3.6 | 2.6 | 3.0 | 2.3 12 |
| Equity ratio 3 | 37 % | 34 % | 40 % | 38 % | 44 % |
| Investments 4 | 931 | 4,617 | 1,318 | 4,314 | 2,247 |
| Profitability | |||||
| EBIT margin | 14.5 % | 14.0 % 1 | 14.2 % | 13.4 % | 12.3 % |
| Return on equity after taxes (ROE) 5, 7, 10, 11 | 12.0 % | 10.5 % | 12.0 % | 10.4 % | 11.4 % |
| Return on operating assets (ROOA) 5, 6, 10 | 10.5 % | 9.8 % | 11.4 % | 10.4 % | 11.7 % |
| Return on invested capital (ROIC) 5, 6, 10 | 8.2 % | 7.3 % | 8.4 % | 7.4 % | 8.0 % |
| Dividend per ordinary share in € | 0.75 8 | 0.70 | 0.66 | 0.57 | 0.49 9 |
| Dividend per preference share in € | 0.76 8 | 0.71 | 0.67 | 0.58 | 0.50 9 |
| Employees (December 31) | 130,510 | 122,217 | 114,181 | 104,872 | 91,971 |
Continue reading:
To our shareholders
To our shareholders